NCT04624646 (CANDLE-AF) is a NA clinical trial of Discontinuous monitoring in Atrial Fibrillation, sponsored by Ewha Womans University Mokdong Hospital.

Who is sponsoring NCT04624646?

NCT04624646 is sponsored by Ewha Womans University Mokdong Hospital.

What drugs are being tested in NCT04624646?

Interventions in NCT04624646: Discontinuous monitoring, Continuous single-lead ECG Patch, 24-hour Holter monitoring.

What condition does NCT04624646 study?

NCT04624646 studies Atrial Fibrillation, Ischemic Stroke, Transient Ischemic Attack.

Is NCT04624646 still recruiting?

NCT04624646 is currently status unknown. Last updated 26 January 2023.

Last reviewed 2023-01-26 · How we verify

NCT04624646: CANDLE-AF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Implication of Atrial Fibrillation Detection Using Wearable Device in Patients With Cryptogenic Stroke

Status unknown NA Last updated 26 January 2023

What this trial tests

NA trial testing Discontinuous monitoring in Atrial Fibrillation in 600 participants. Status unknown.

Timeline

17 November 2020

Primary endpoint
18 September 2024

18 September 2025

Quick facts

Lead sponsor	Ewha Womans University Mokdong Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	screening
Enrollment	600
Start date	17 November 2020
Primary completion	18 September 2024
Estimated completion	18 September 2025
Sites	9 locations across South Korea

Drugs / interventions tested

Discontinuous monitoring
Continuous single-lead ECG Patch
24-hour Holter monitoring

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →
Ischemic Stroke — all drugs for Ischemic Stroke →
Transient Ischemic Attack — all drugs for Transient Ischemic Attack →

Sponsor

Ewha Womans University Mokdong Hospital

Who can join

Adults 20 to 80, any sex, with Atrial Fibrillation or Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is known that atrial fibrillation after stroke significantly increases the risk of stroke or systemic embolism. Accordingly, efforts have been made to detect hidden atrial fibrillation and apply treatment using anticoagulants instead of antiplatelet agents. The conventional method used to screen for atrial fibrillation in stroke patients who did not have atrial fibrillation at first admission is 24-hour Holter monitoring. This study will compare the detection rate of atrial fibrillation with discontinuous ECG monitoring three times a day and 72 hours of single-lead ECG patch monitoring compared with the conventional Holter test.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Atrial fibrillation: epidemiology, screening and digital health.
Linz D, Gawalko M, Betz K, Hendriks JM, et al · · 2024 · cited 230× · PMID 38362546 · DOI 10.1016/j.lanepe.2023.100786

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Other Ewha Womans University Mokdong Hospital trials

Trials by the same sponsor.

NCT07496281 — OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation · Phase 4 · not yet recruiting
NCT07497893 — FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anti · NA · not yet recruiting
NCT06929897 — PVI Alone vs PVI With Posterior Wall Isolation for Pulse-Field Ablation in Persistent AF · NA · not yet recruiting
NCT06889818 — Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ) · recruiting
NCT06051162 — HPI Effect in Robotic Urological Surgery on AKI · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04624646 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ewha Womans University Mokdong Hospital
Last refreshed: 26 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04624646.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing